SOURCE: DNAPrint Genomics, Inc.

January 30, 2008 07:30 ET

DNAPrint Genomics Helps Boulder Police Solve 10-Year-Old Rape/Murder Case Using Cutting Edge DNA Technology

SARASOTA, FL--(Marketwire - January 30, 2008) - DNAPrint Genomics, Inc. (OTCBB: DNAG) today announced that it has helped the Boulder, Colo. Police Department solve a 10-year-old rape and murder case involving a 23-year old University of Colorado student by using the Company's proprietary DNAWitness 2.5 product. Subsequently, detectives arrested Diego Olmos-Alcalde on Jan. 27th after a DNA match linking the 38-year-old suspect to the victim's slaying.

The victim, Susannah Chase, was savagely raped and beaten with a baseball bat in December of 1997 as she walked home alone after getting pizza. She died hours after the attack of severe head injuries.

Ms. Chase's murder was filed as a cold case until December of 2003 when detectives from the Boulder Police Department contacted DNAPrint Genomics after hearing about the Company's successful work behind the Derrick Todd Lee serial killer case in Louisiana. Using state-of-the-art DNA testing technology, the Company issued its findings in January of 2004 and determined the suspect's genetic ancestry was consistent with a Hispanic or Native American background. With this information and with many more years of detailed investigations, police were able to link Mr. Olmos-Alcalde, a Chilean native with Denver-area ties and a record of past sexual assault charges.

"Our investigators were determined to use all the resources that were available in their search for Susannah Chase's killer," said Boulder Police Chief Mark Beckner. "This technology gave our detectives a focus and direction that turned out to be right on the mark."

"Our involvement in the Chase murder case is solid evidence that we are second to none in DNA testing accuracy," said Richard Gabriel, CEO and President of DNAPrint Genomics, Inc. "Police agencies from all over the world rely on our technology and support as they attempt to solve difficult cases. We are very happy and proud to have helped solve this heinous crime so that Ms. Chase's family may see justice in this case and can finally have closure in their lives."

Mr. Gabriel also noted that the Company has created a not-for-profit foundation to award grants, both in cash and in-kind donations of services from DNAPrint Genomics and other biotechnology companies, to law enforcement agencies having unsolved cases involving DNA evidence.

The foundation, Beyond CODIS, Inc., is a Florida-based corporation that in addition to awarding grants, will conduct seminars to discuss the application of the newest advances in DNA forensic analysis, assist law enforcement agencies in using DNA technology to identify unknown victims and help provide evidence at trial in order to exonerate an innocent person who has been wrongly convicted of a crime.

How DNAWitness™2.5 Works

Law enforcement officers use DNAWitness™2.5 to determine genetic ancestry from DNA samples obtained from crime scenes, narrowing the potential suspect pool to a more focused group of likely candidates. The test enables law enforcement agencies to reduce both the cost and time needed to apprehend suspects. Current forensic DNA products in the market act like a fingerprint and can only be used to match DNA specimens. DNAWitness 2.5 is the first forensic product that provides predictive capability. Initial DNAWitness 2.5 customers include medical examiner's offices, special task forces, sheriffs' departments, and district attorney's offices from various cities. These cities include the three largest U.S. metropolitan areas of New York City, Los Angeles, and Chicago.

About DNAPrint Genomics, Inc.

DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS™, RETINOME™, ANCESTRYbyDNA™ and EURO-DNA™. DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

Contact Information

  • Company Contact:
    Richard Gabriel
    CEO and President
    941 366-3400

    Ron Stabiner
    The Wall Street Group, Inc.
    212-888-4848